Banner Text

Banner Slogan

Member Login
User Name:
Password:
Register
Street Address
Suburb Postcode
STATE  Australia
Tel Phone
Fax Fax
Email Us

About Us

Ovplex Logo small mb blue background coloured in.JPG

A superior performing alternative to CA125 for the diagnostic process to check for ovarian cancer in symptomatic women

Welcome to HealthLinx Limited

HealthLinx is an emerging biomarker and diagnostic company with an integrated platform in biomarker and bioactive peptide discovery platforms. Our core focus is on the development of novel blood based diagnostics for targeted diseases that have un-met market need.

Clinical practice and public health are moving from generic, episodic treatment approaches towards personalised and preventive medicine. The trend in the pharmaceutical industry is towards developing better and earlier diagnostics and disease-targeted therapies. Food companies are also directing focus to functional foods as a means of improving community health. These market trends converge and are aligned with HealthLinx’s vision and mission.
 

 

HealthLinx will be recognised as a leader in delivering diagnostic applications to improve health outcomes.


HealthLinx develops novel, non-invasive, serum-based, diagnostic products. The Ovarian Cancer Program has completed a phase II biomarker trial with the outcome being the development of the first generation ovarian cancer diagnostic, OvPlex™.

 

OvPlex™ is a panel of five markers including the gold standard CA125. The trial screened 150 diseased samples and 212 normal samples. Statistical significance was achieved demonstrating OvPlex™ is a better performing diagnostic than CA125 as intrepreted by an independent biostatistician. 

 

The company released OvPlex™ in the Australian market in October 2008 through its distribution partner, ARL Pathology (now Healthscope), as an elective test. OvPlex™ was released in the United Kingdom and Republic of Ireland in February 2010 through distribution partner Intus Healthcare and is on-sold by Spire Healthcare.  
 

 

Diagnostics

diag_image.jpg

Unlike the therapeutics’ market, where it can take up to 15 years and US$1billion to get a drug from discovery to the market, a diagnostic will usually take less than a third of that time and less than 10% of the cost.
read more

Analyst Research

nutra_image.jpg

Independent analyst research reports on HealthLinx Limited.

 

read more

 

 

 

LATEST NEWS

16 December 2011

HealthLinx to finalise recruitment for OvPlex study due to excellent results

line.jpg

8 December 2011

HealthLinx signs convertible note funding agreement for up to $9 million

line.jpg
22 November 2011

Heads of Agreement signed for OvPlex™ distribution in Spain

line.jpg
16 November 2011

HealthLinx CEO to resign as of 30th June 2012

line.jpg
10 November 2011

Prostate cancer collaboration to continue with Garvan Institute

line.jpg
2 November 2011

Results of AGM

line.jpg

2 November 2011

Chairman's address to shareholders

line.jpg

26 October 2011

OvPlex™ patent granted in Hong Kong

line.jpg

11 October 2011

Second OvPlex™ trial reports increased diagnostic efficiency

Web Design by WebAlive